At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 30 target
Drug / intervention
SHR-A1811 plus AK112drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of SHR-A1811 Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With HER2 Abnormalities
In Brief
A Phase 2 clinical trial evaluating SHR-A1811 plus AK112 for Non-Small Cell Lung Cancer. Not yet recruiting, targeting 30 participants.
Detailed Summary
This is a phase II, open-label, single-arm study evaluating the efficacy and safety of SHR-A1811 (a HER2-targeted ADC) combined with AK112 (a PD-1/VEGF bispecific antibody) in patients with HER2-amplified or overexpressed locally advanced or metastatic NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
Countries--
Collaborators--
Timeline
Phase 2Not Yet Recruiting
202720282029
First PostedMar 2026
Enrollment StartApr 2026
TodayJul 2026
Primary CompletionDec 2027
Study CompletionDec 2028
First PostedMar 24, 2026
Enrollment StartApr 30, 2026
Primary CompletionDec 31, 2027
Study CompletionDec 31, 2028
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 3 months agoPrimary completion in 1.5 years
Interventions
SHR-A1811 plus AK112drug
Patients will receive the combination of SHR-A1811 and AK112 until disease progression or until other predefined discontinuation criteria are met, whichever occurs first.